This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix ...

CHATHAM, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and ...

A cost-saving effort by NHS England to transition multiple sclerosis (MS) patients from Biogen Inc’s (NASDAQ:BIIB) Tysabri (natalizumab) to the biosimilar drug Tyruko has led to significant side ...

Stoke Therapeutics Inc. and Biogen Inc. said Tuesday they are entering a collaboration to develop and commercialize a treatment for Dravet syndrome, a severe form of epilepsy that starts in childhood.

Deep-pocketed investors have adopted a bullish approach towards Biogen BIIB, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...

Biogen and Stoke Therapeutics have announced a partnership aimed at advancing a disease-modifying treatment for Dravet syndrome, with the deal worth $550m. Up to 38,000 people in the US, UK, EU and ...

Biogen secures rights to commercialize zorevunersen outside North America, while Stoke leads global development and retains U.S. rights. Stoke receives $165 million upfront, up to $385 million in ...

CAMBRIDGE, Mass. & BEDFORD, Mass.--(BUSINESS WIRE)--Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK) today announced a collaboration for the ...

Providing a diverse range of perspectives from bullish to bearish, 10 analysts have published ratings on Biogen (NASDAQ:BIIB) in the last three months. The following table summarizes their recent ...

Biogen Inc.’s stock BIIB tumbled 7% Wednesday, after the biotech beat fourth-quarter earnings estimates but offered guidance that lagged behind consensus, as sales of its multiple sclerosis drug ...

Biogen expects 2025 non-GAAP EPS of $15.25-$16.25 and a mid-single-digit decline in total revenue, primarily due to MS franchise pressures, including potential biosimilar and generic entries ...